drugset / Trial / NCT00251979

A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer

NCT00251979

Phase 3 Completed 1312 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindPrevention

Summary

This study is being carried out to see if constant 3 days infusion of Nexium is effective in preventing rebleeding after an endoscopic treatment.

Timeline

Start
2005-10
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 8 mg Intravenous
Subject Esomeprazole Small molecule 40 mg Intravenous

Indications

No indication recorded.